Health Trials

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

ConditionsOverweightObesity
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEli Lilly and Company

About this trial

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Eligibility criteria

Qualifiers

See Master Protocol CWMM (NCT06143956) for inclusion criteria

Disqualifiers

Have type 1 diabetes or type 2 diabetes

Have an ongoing history of bradyarrhythmia and/or sinus bradycardia

Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)

Have a history of acute or chronic pancreatitis

Trial design

Treatments tested in this trial

  • Macupatide
  • Eloralintide
  • Placebo

Treatment groups

400 Participants
are divided into 8 treatment groups

8

Treatment groups

See each treatment group below.

Sponsors and collaborators

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov